Akebia guides cash runway of at least two years, funding Vafseo launch and pipeline

Akebia Therapeutics, Inc.

Expects existing cash and cash from ops to fund current plan for at least two years.
Funding supports U.S. Vafseo launch and planned pipeline advancement.
CEO John Butler presenting at 43rd Annual J.P. Morgan Healthcare Conference on Jan 16, 2025.
Cautionary language regarding potential need for additional funding if plan changes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.